ID16969A - ARIL PIRIMIDIN'S DEMONS - Google Patents
ARIL PIRIMIDIN'S DEMONSInfo
- Publication number
- ID16969A ID16969A IDP971727A ID971727A ID16969A ID 16969 A ID16969 A ID 16969A ID P971727 A IDP971727 A ID P971727A ID 971727 A ID971727 A ID 971727A ID 16969 A ID16969 A ID 16969A
- Authority
- ID
- Indonesia
- Prior art keywords
- pirimidin
- demons
- aril
- aril pirimidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1821896P | 1996-05-23 | 1996-05-23 | |
US4037797P | 1997-03-10 | 1997-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ID16969A true ID16969A (en) | 1997-11-27 |
Family
ID=26690869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDP971727A ID16969A (en) | 1996-05-23 | 1997-05-23 | ARIL PIRIMIDIN'S DEMONS |
Country Status (32)
Country | Link |
---|---|
US (1) | US5863924A (en) |
EP (1) | EP0901474B1 (en) |
JP (1) | JP2001525794A (en) |
KR (1) | KR100518101B1 (en) |
CN (1) | CN1109675C (en) |
AR (1) | AR007253A1 (en) |
AT (1) | ATE323682T1 (en) |
AU (1) | AU725891B2 (en) |
BR (1) | BR9709599A (en) |
CA (1) | CA2255705A1 (en) |
CO (1) | CO4950514A1 (en) |
CZ (1) | CZ291849B6 (en) |
DE (1) | DE69735712T2 (en) |
DK (1) | DK0901474T3 (en) |
ES (1) | ES2262178T3 (en) |
HK (1) | HK1020345A1 (en) |
HR (1) | HRP970275B1 (en) |
HU (1) | HUP9901535A3 (en) |
ID (1) | ID16969A (en) |
IL (1) | IL127056A (en) |
MA (1) | MA26431A1 (en) |
MY (1) | MY119181A (en) |
NO (1) | NO311800B1 (en) |
NZ (1) | NZ332802A (en) |
PT (1) | PT901474E (en) |
RU (1) | RU2189976C2 (en) |
SA (2) | SA05260356B1 (en) |
TR (1) | TR199802391T2 (en) |
TW (1) | TW440563B (en) |
UY (1) | UY24560A1 (en) |
WO (1) | WO1997044326A1 (en) |
YU (1) | YU53298A (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9814458A (en) * | 1997-09-02 | 2001-10-23 | Du Pont Pharm Co | Compound, pharmaceutical composition and method of treating affective disorders |
US6040315A (en) * | 1997-10-30 | 2000-03-21 | Day; Charles E. | Antacid co-polymer of guanidine and polyethylenimine |
DE19844291A1 (en) * | 1998-09-18 | 2000-03-23 | Schering Ag | New aminoalkylaminoalkyl-substituted benzoxazines or benzothiazines, are nitrogen monoxide synthase inhibitors useful for treating neurodegenerative, inflammatory, autoimmune or cardiovascular disease |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
EP1144390A2 (en) * | 1999-01-22 | 2001-10-17 | Amgen Inc., | Kinase inhibitors |
EP1057831B1 (en) * | 1999-05-26 | 2004-09-22 | F. Hoffmann-La Roche Ag | Process for the preparation of vinyl pyrimidine derivatives |
ATE250417T1 (en) * | 1999-07-30 | 2003-10-15 | Pharmagene Lab Ltd | USE OF 2-AMINO-4-(4-FLUORONAPHTH-1-YL)-6- ISOPROPYLPYRIMIDINES FOR THE TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT |
GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
DE60023926T2 (en) | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | TYROSINE KINASE INHIBITORS |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
RU2277911C2 (en) * | 2000-02-25 | 2006-06-20 | Ф.Хоффманн-Ля Рош Аг | Modulators of adenosine receptors |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US6444477B1 (en) | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
WO2002092090A1 (en) * | 2001-05-14 | 2002-11-21 | Bristol-Myers Squibb Pharma Company | Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
WO2002102313A2 (en) * | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
ES2255621T3 (en) | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | THYROSINE KINASE INHIBITORS. |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2472763A1 (en) * | 2002-02-13 | 2003-08-21 | Pharmagene Laboratories Limited | 5-ht2b receptor antagonists |
GB0203412D0 (en) * | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
WO2003076434A1 (en) | 2002-03-09 | 2003-09-18 | Astrazeneca Ab | 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US20040023978A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Active salt forms with tyrosine kinase activity |
US20040023981A1 (en) * | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
ES2337782T3 (en) * | 2002-07-29 | 2010-04-29 | Rigel Pharmaceuticals, Inc. | METHODS TO TREAT OR PREVENT AUTOIMMUNITY DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS. |
SI1625121T1 (en) * | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7109337B2 (en) * | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
US20090018150A1 (en) * | 2003-07-24 | 2009-01-15 | Asterand Uk Limited | 5-Ht2b Receptor Antagonists |
MXPA06000771A (en) * | 2003-07-25 | 2006-04-18 | Ciba Sc Holding Ag | Use of substituted 2,4-bis (alkylamino) pyrimidines or -quinazolines as antimicrobials. |
NZ545270A (en) * | 2003-07-30 | 2010-04-30 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
WO2005040135A1 (en) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | Antistress drug and medical use thereof |
EP1713775A4 (en) * | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | Chemical compounds |
TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
EP1716867A4 (en) | 2004-02-20 | 2009-09-23 | Astellas Pharma Inc | Preventives for migraine |
AU2005232745A1 (en) * | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
WO2005111022A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP2007537235A (en) * | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | Pyrimidine derivatives for the treatment of abnormal cell proliferation |
US20060205945A1 (en) * | 2004-05-14 | 2006-09-14 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
AU2005286592A1 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
ES2380550T3 (en) * | 2004-11-24 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Spiro-2,4-pyrimidinediamine compounds and their uses |
GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
KR101278397B1 (en) | 2005-01-19 | 2013-06-25 | 리겔 파마슈티칼스, 인크. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
CN101151249B (en) * | 2005-03-31 | 2011-04-06 | 辉瑞产品公司 | Cyclopentapyridine and tetrahydroquinoline derivatives |
WO2007027238A2 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
AU2006259525B2 (en) * | 2005-06-14 | 2012-05-24 | Gpcr Therapeutics, Inc | Pyrimidine compounds |
JP2009512636A (en) | 2005-09-30 | 2009-03-26 | アストラゼネカ アクチボラグ | Imidazo [1,2-a] pyridines having cell growth inhibitory action |
US20080293942A1 (en) * | 2005-11-28 | 2008-11-27 | Cousins Russell D | Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives |
MX2008010644A (en) | 2006-02-20 | 2008-10-28 | Astellas Pharma Inc | Pyrrole derivative or salt thereof. |
AR061185A1 (en) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | HETEROCICLICAL COMPOUNDS AS INHIBITORS OF HSP90. PHARMACEUTICAL COMPOSITIONS. |
CA2672639A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
WO2008105526A1 (en) | 2007-03-01 | 2008-09-04 | Chugai Seiyaku Kabushiki Kaisha | Macrocyclic compound |
UA97834C2 (en) | 2007-04-18 | 2012-03-26 | Пфайзер Продактс Инк. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
KR101294731B1 (en) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | Array substrate, display panel having the array substrate and method of manufacturing the array substrate |
JP5599312B2 (en) * | 2007-08-22 | 2014-10-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 5- (4- (haloalkoxy) phenyl) pyrimidin-2-amine compounds and compositions as kinase inhibitors |
RU2378278C2 (en) * | 2008-01-24 | 2010-01-10 | Андрей Александрович Иващенко | SUBSTITUTED 3-SULPHONYL-[1,2,3]TRIAZOLO[1,5-a]PYRIMIDINES-ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHOD OF PRODUCING SAID COMPOUNDS AND USE |
AU2009215541A1 (en) | 2008-02-19 | 2009-08-27 | Adolor Corporation | Beloxepin, its enantiomers, and analogs thereof for the treatment of pain |
EA019289B1 (en) | 2008-04-21 | 2014-02-28 | Тайджен Байотекнолоджи Ко., Лтд. | Aminopiridin, aminopirimidin and amino-1,3,5-triazine derivatives |
CA2760911A1 (en) * | 2009-05-19 | 2010-11-25 | George E. Davis | Compounds and methods for controlling fungi |
NZ601508A (en) | 2009-12-30 | 2013-07-26 | Arqule Inc | Substituted naphthalenyl-pyrimidine compounds and the use thereof in the treatment of cancer |
CN102786512A (en) * | 2012-05-31 | 2012-11-21 | 中国人民解放军军事医学科学院毒物药物研究所 | N-aryl unsaturated fused ring tertiary amine compound, preparation method thereof and application thereof to tumor resistance |
JP6779867B2 (en) * | 2014-06-13 | 2020-11-04 | ユマ セラピューティクス,インコーポレーテッド | Pyrimidine compounds and how to use them |
CN104725322B (en) * | 2015-02-16 | 2017-05-24 | 同济大学 | 2-amido pyrimidine compound and preparation method thereof |
WO2016173438A1 (en) | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
RU2605265C1 (en) * | 2015-10-06 | 2016-12-20 | федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) | Analgesic and anti-inflammatory agent based on 5-butyl-6-hydroxy-2-methyl pyrimidine-4(3h)-one |
WO2017205459A1 (en) | 2016-05-26 | 2017-11-30 | Kalyra Pharmaceuticals, Inc. | Egfr inhibitor compounds |
AU2018352695A1 (en) | 2017-10-19 | 2020-05-28 | Effector Therapeutics, Inc. | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 |
CN108904503B (en) * | 2018-07-02 | 2021-09-28 | 陕西科技大学 | Application of 6-chloro-5-nitro-2, 4-diaminopyrimidine in medicine for treating chronic granulocytic leukemia |
TWI782504B (en) | 2020-05-08 | 2022-11-01 | 美商美國禮來大藥廠 | (trifluoromethyl)pyrimidine-2-amine compounds |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3535330A (en) * | 1968-04-29 | 1970-10-20 | Sandoz Ag | 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof |
US3965101A (en) * | 1973-07-26 | 1976-06-22 | E. R. Squibb & Sons, Inc. | 1-(O-Bromo-phenoxyalkyl)-1,2-dihydro-2-iminopyrimidines |
DE2750288A1 (en) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | NEW 9- (OMEGA-HETEROARYLAMINO-ALKYLAMINO) -ERYTHROMYCINE, THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF AND THE MEDICINAL PRODUCTS CONTAINING THEM |
US5002951A (en) * | 1979-03-19 | 1991-03-26 | The Upjohn Company | Method for treating bacterial and protozoal infections |
US4543248A (en) * | 1979-03-19 | 1985-09-24 | The Upjohn Company | Method for immunoregulation with 6-aryl pyrimidine compounds |
US4665077A (en) * | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
GB2056449A (en) * | 1979-08-08 | 1981-03-18 | Searle & Co | 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides |
US4619933A (en) * | 1979-09-28 | 1986-10-28 | The Upjohn Company | 6-aryl pyrimidines for treating aplastic anemia |
FR2539741A1 (en) * | 1983-01-21 | 1984-07-27 | Sanofi Sa | DIAZOTE HETEROCYCLIC CORE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS ACTIVE ON THE CENTRAL NERVOUS SYSTEM CONTAINING THE SAME |
US4512993A (en) * | 1983-07-25 | 1985-04-23 | Sterling Drug Inc. | 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof |
US4504482A (en) * | 1983-07-28 | 1985-03-12 | Sterling Drug Inc. | [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof |
WO1986004583A1 (en) * | 1985-02-05 | 1986-08-14 | The Upjohn Company | 4-substituted-6-aryl pyrimidine compounds |
US4711888A (en) * | 1985-07-24 | 1987-12-08 | Pfizer Inc. | Hydroxy and alkoxy pyrimidines |
US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
WO1989011279A1 (en) * | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
HU206337B (en) * | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
IE63502B1 (en) * | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
GB9012311D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
JP2648897B2 (en) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | Pyrimidine derivatives |
DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
US5698444A (en) * | 1993-12-23 | 1997-12-16 | Eli Lilly And Company | Serotonin receptor protein and related nucleic acid compounds |
US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
ATE226574T1 (en) * | 1995-04-13 | 2002-11-15 | Taiho Pharmaceutical Co Ltd | 4,6-DIARYLPYRIMIDINE DERIVATIVES AND SALTS THEREOF |
US5795905A (en) * | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
-
1997
- 1997-05-09 TW TW086106209A patent/TW440563B/en not_active IP Right Cessation
- 1997-05-14 IL IL12705697A patent/IL127056A/en not_active IP Right Cessation
- 1997-05-14 DE DE69735712T patent/DE69735712T2/en not_active Expired - Fee Related
- 1997-05-14 HU HU9901535A patent/HUP9901535A3/en unknown
- 1997-05-14 BR BR9709599A patent/BR9709599A/en not_active Application Discontinuation
- 1997-05-14 DK DK97923071T patent/DK0901474T3/en active
- 1997-05-14 AT AT97923071T patent/ATE323682T1/en not_active IP Right Cessation
- 1997-05-14 ES ES97923071T patent/ES2262178T3/en not_active Expired - Lifetime
- 1997-05-14 WO PCT/EP1997/002454 patent/WO1997044326A1/en active IP Right Grant
- 1997-05-14 CA CA002255705A patent/CA2255705A1/en not_active Abandoned
- 1997-05-14 EP EP97923071A patent/EP0901474B1/en not_active Expired - Lifetime
- 1997-05-14 KR KR10-1998-0709451A patent/KR100518101B1/en not_active IP Right Cessation
- 1997-05-14 PT PT97923071T patent/PT901474E/en unknown
- 1997-05-14 CN CN97196018A patent/CN1109675C/en not_active Expired - Fee Related
- 1997-05-14 JP JP54148297A patent/JP2001525794A/en not_active Ceased
- 1997-05-14 TR TR1998/02391T patent/TR199802391T2/en unknown
- 1997-05-14 RU RU98123001/04A patent/RU2189976C2/en not_active IP Right Cessation
- 1997-05-14 CZ CZ19983803A patent/CZ291849B6/en not_active IP Right Cessation
- 1997-05-14 AU AU28978/97A patent/AU725891B2/en not_active Ceased
- 1997-05-14 NZ NZ332802A patent/NZ332802A/en unknown
- 1997-05-20 US US08/858,964 patent/US5863924A/en not_active Expired - Fee Related
- 1997-05-20 HR HR970275A patent/HRP970275B1/en not_active IP Right Cessation
- 1997-05-20 MY MYPI97002204A patent/MY119181A/en unknown
- 1997-05-21 MA MA24630A patent/MA26431A1/en unknown
- 1997-05-22 AR ARP970102176A patent/AR007253A1/en unknown
- 1997-05-22 UY UY24560A patent/UY24560A1/en not_active IP Right Cessation
- 1997-05-22 CO CO97028097A patent/CO4950514A1/en unknown
- 1997-05-23 ID IDP971727A patent/ID16969A/en unknown
- 1997-07-01 SA SA05260356A patent/SA05260356B1/en unknown
- 1997-07-01 SA SA97180191A patent/SA97180191B1/en unknown
-
1998
- 1998-11-19 NO NO19985392A patent/NO311800B1/en not_active Application Discontinuation
- 1998-11-23 YU YU53298A patent/YU53298A/en unknown
-
1999
- 1999-11-29 HK HK99105532A patent/HK1020345A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID16969A (en) | ARIL PIRIMIDIN'S DEMONS | |
ID18623A (en) | NAFTIRIDIN'S DEMONS | |
ID26277A (en) | QUINOLINA'S DEMONS | |
ID21194A (en) | D-PROLINA'S DEMONS | |
DE59605821D1 (en) | 1/4 SCALLABSORBER | |
ID17440A (en) | PEPTIDA'S DEMONSTRATIONS | |
ID23861A (en) | AMINOPIRIMIDINE'S DEMONS | |
ID16037A (en) | PEPTIDA'S DEMONSTRATIONS | |
ID29173A (en) | CARBAPENEM'S DEMONS | |
NO992059D0 (en) | 2 metoksyfenylpiperazinderivater | |
NO960353D0 (en) | 4 aminobenzoylguanidinderivater | |
BR9709521A (en) | "3-Cyanoaryl-pyrazoles" | |
NO960392L (en) | 4 merkaptobenzoylguanidinderivater | |
ID21890A (en) | PIPERIDINA'S DEMONS | |
ID16747A (en) | QUINOLINA'S DEMONS | |
FR2724251B3 (en) | LABELING STRUCTURE | |
FR2735986B3 (en) | HALTERA EXTENSION | |
DE69405544T2 (en) | 4'-0-SULFONYLANTHRACYCLINE DERIVATIVES | |
KR960001317U (en) | Castereo's fixed structure | |
BR9606017A (en) | "Enrotrilan" | |
ITCT940031A0 (en) | "SBUFFI" | |
BR7401400U (en) | "Cool-fast | |
UA27881C2 (en) | WASHING-DISINFECTANT "ZBRUCH-2" | |
UA680S (en) | SHIP-SERVICE-TRAVEL | |
UA1384S (en) | LABEL "NARZAN" |